Canine IL-6 Antibody

Catalog #: MAB1609 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB1609
MAB1609-SP

Cell Proliferation Induced by IL‑6 and Neutralization by Canine IL‑6 Antibody.

1 Image

All IL-6 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Canine IL-6 Antibody Summary

Species Reactivity

Canine

Specificity

Detects canine IL-6 in direct ELISAs. In direct ELISAs, no cross‑reactivity with recombinant mouse (rm) Cardiotrophin-1, recombinant human (rh) CLC, recombinant rat (rr) CNTF, recombinant cotton rat IL-6, recombinant equine IL-6, rhIL-6, recombinant porcine IL-6, rrIL-6, rmIL-11, rmLIF, or rmOncostatin M is observed.

Source

Monoclonal Mouse IgG_2A Clone # 247017

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant canine IL‑6
Thr23-Met207
Accession # P41323

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. The Neutralization Dose (ND₅₀) is typically 10-30 µg/mL in the presence of 50 ng/mL Recombinant Canine IL‑6.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by IL‑6 and Neutralization by Canine IL‑6 Antibody. Recombinant Canine IL-6 (Catalog # 1609-CL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Canine IL-6 (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Canine IL-6 Monoclonal Antibody (Catalog # MAB1609). The ND₅₀ is typically 10-30 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-6

Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature canine IL-6 is 187 amino acids (aa) in length and shares 76%, 59%, 38%, and 40% aa sequence identity with feline, human, mouse, and rat IL-6, respectively (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130‑expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL‑6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8).

References

Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
Jones, S.A. (2005) J. Immunol. 175:3468.
Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
Kukielka, G.L. et al. (1995) Circulation 92:1866.
Murakami, M. et al. (1993) Science 260:1808.
Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.

Long Name

Interleukin 6

Entrez Gene IDs

3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 102138971 (Cynomolgus Monkey); 100034196 (Equine); 493687 (Feline); 463288 (Primate); 100008733 (Rabbit)

Alternate Names

B-cell differentiation factor; B-cell stimulatory factor 2; BSF2; BSF-2; CDF; CTL differentiation factor ; HSF; hybridoma growth factor; IFNB2; IFN-beta-2; IL6; IL-6; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2A